David McDermott, M.D.

Beth Israel Deaconess Medical Center

Chief, Division of Medical Oncology

Harvard Medical School

Professor of Medicine

David McDermott, MD | Kidney Cancer Research Consortium
Dr. David McDermott, is a distinguished figure in the field of medical oncology, serving as a beacon of expertise at Beth Israel and Harvard Medical School. His clinical interests, spanning immunotherapy for solid tumors, kidney cancer, melanoma, and medical oncology, showcase a comprehensive approach to tackling complex malignancies. Dr. McDermott’s contributions extend beyond clinical practice, making him a luminary in both academic and healthcare spheres.


Educational Background:

Dr. McDermott earned his board certification in Medical Oncology from the American Board of Internal Medicine reflecting not only his commitment to specialized knowledge but also his dedication to staying at the forefront of advancements in cancer care.


Education & Training:

Medical School:
Weill Medical College of Cornell University
Tufts Medical Center
Tufts Medical Center
Tufts Medical Center



Professional Appointments & Responsibilities:

At Beth Israel, Dr. McDermott holds the pivotal position of Chief of the Division of Medical Oncology, steering the institution’s efforts in delivering cutting-edge oncological care. Simultaneously, his role as a Professor of Medicine at Harvard Medical School attests to his commitment to educating and inspiring the next generation of medical professionals.



Clinical Expertise:

Immunotherapy, a groundbreaking approach in cancer treatment, is an area where Dr. McDermott has made significant contributions. His work in advancing immunotherapeutic strategies for solid tumors, particularly in the context of kidney cancer and melanoma, underscores his commitment to pushing the boundaries of available treatments.


Leadership & Impact:

In summary, Dr. David McDermott’s career is marked by a relentless pursuit of excellence in both clinical practice and academia. His leadership at Beth Israel, coupled with his role as a Professor at Harvard Medical School, underscores his commitment to advancing medical knowledge, educating future generations, and making a lasting impact on the landscape of medical oncology.


Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Naomi Haas, MD | Kidney Cancer Research Consortium

Naomi Haas


Daniel George, MD | Kidney Cancer Research Consortium

Daniel George

Duke University

Hans Hammers

UT Southwestern

Eric Jonasch, M.D. | Kidney Cancer Research Consortium

Eric Jonasch

MD Anderson

Brian Rini, MD | Kidney Cancer Research Consortium

Brian Rini

Vanderbilt University

Ulka Vaishampayan, MD | Kidney Cancer Research Consortium

Ulka Vaishampayan

University of Michigan